CDKN2B and venous thromboembolism: Somatic tumor mutations in STK11, KRAS, CTNNB1, KEAP1, CDKN2B and MET, which were reported to be associated with cancer-induced venous thromboembolism in an independent study [12], were infrequent in OSCC.